Lion TCR Shines at 2025 Singapore NATi RNA Therapeutics Symposium: mRNA-Encoded TCR-T Therapy Drives New Breakthroughs in Oncology
Lion TCR
Developer of Novel Immunotherapies
2025Singapore Nucleic Acid Drug Development Program (Nucleic Acid Therapeutics Initiative`, abbreviated as`NATi）RNAThe seminar concluded successfully in Singapore recently.NATiIt was developed by the Agency for Science, Technology and Research (A*STAR) The national platform hosted by aims to establish Singapore as a regional hub for nucleic acid therapeutics research, clinical translation, and commercialization. By advancing this initiative, Singapore will support and develop more local SMEs and startups while attracting global companies to set up operations. The seminar brings together leading experts to discuss the future of nucleic acid therapeutics and Singapore's role in advancingRNAEffects of the drug.In this event, Laien Bio (Lion TCR) Relying on its expertise inmRNACodingTCR-TInnovative achievements in the field of cell therapy have become one of the highlights that have attracted much attention.
The Laien Bio team showcased the company's technical strength and innovative concepts at this seminar. Dr. Tingting Wang, Chief Operating Officer and Chief Medical Officer of Laien Bio, and Dr. Lu'en Wei, Senior Director of Research and Development (Dr. Lu-En Wai`) represented Guangzhou Laien Biological Medicine Co., Ltd. at the event. Dr. Wang Tingting delivered a keynote speech at the conference.`
Dr. Wang Tingting gave a detailed introduction to the leading product of Guangzhou Laien Biological Medicine Co., Ltd. in her speech.LioCyx-M004Mainly used for the treatment of hepatitis B virus-related hepatocellular carcinoma. The product is based onmRNATechnical development offers greater flexibility, shorter production cycles, and enhanced security.At the same time, Dr. Wang Tingting also sharedLioCyx-M004The latest clinical data, the product received approval from the U.S. Food and Drug Administration (FDA) this February.FDA) approved, entering international multicenter2Phase Clinical Trial.
Dr. Wang Tingting (fifth from the right), Chief Operating Officer and Chief Medical Officer of Guangzhou Laien Biological Medicine Co., Ltd., and Dr. Wei Lu'en (fourth from the right), Senior Director of Research and Development, attended on behalf of the company.NATi RNA Seminar
NATiProvided an excellent opportunity for knowledge exchange and collaboration for scientific researchers, business representatives, and industry experts worldwide. Through such a grand event, all parties can share the latest research achievements, discuss the challenges and opportunities facing the industry, and jointly promoteRNAThe continuous development and innovation of treatment technologies. Guangzhou Laien Biological Medicine Co., Ltd. continues to commit tomRNACodingTCR-TThe therapy achieved a breakthrough in clinical research, actively promoting its global clinical trial progress.
About Laien Bio
Laien Bio (Lion TCR) Is a biotech company that has entered the clinical stage, focusing onTCRTherapy. The company has used in a forward-looking mannermRNATo encodeTCR, applied in clinical trials for the treatment of liver cancer, demonstrating good safety and significant efficacy, and throughAIEmpoweredTCRDiscover platforms, expand targets and indications, and provide innovative therapies for unresolved clinical issues. Meanwhile, the company has established a platform for autologous cell therapy and off-the-shelf therapeutic products.mRNA-LNPDelivery in vivoTCR-TTherapies, etc.
Highlights:
Major Breakthrough! Laien Bio's Liocyx-M004 Approved by FDA for International Multicenter Phase 2 Clinical Trial to Treat Liver Cancer
World's First! Laien Bio's mRNA-Encoded TCR-T Approved for Clinical Trials, Precisely Targeting Hepatocellular Carcinoma
Guangzhou Laien Biological Medicine Co., Ltd. Honored as "2024 Hurun China Medical New Power Enterprise"
LIONTCR
WeChat ID |Laien Bio
Official Website｜https://www.liontcr.com/